Development Partners

World leaders in their fields

 To drive the development of Apta-1 in the most cost-effective manner, while keeping set schedules, Aptahem collaborates with various consultants and contract research laboratories around the world. Aptahem’s partners are world leaders in their fields, and they meet the, Good Laboratory Practice (GLP) and Good Manufacturing Practice, (GMP) requirements required by Aptahem.

SmiLe Incubator

Aptahem hires a spot in SmiLe Incubator’s laboratory facilities at Medicon Village in Lund, as part of the EU-financed project Open Lab Skåne, to carry out some experiments and tests on its own. The laboratory, equipped with the latest equipment, enables Aptahem to test new theories and concepts around Apta-1. The availability of SmiLe saves a lot of time and resources while there is a large network to be part of.


The Nencki Institute of Experimental Biology has the highest rankings for European research institutes, A +, and is among the leaders in molecular neurobiology, having two “European Centres of Excellence”.
This collaboration will enable the implementation of a thorough evaluation of Apta-1’s biological effects. It will, among other things, help to clarify the anti-inflammatory properties of Apta-1. It is these anti-inflammatory properties that are central to the successful treatment of diseases where harmful activation of the immune system is present, such as sepsis or a wide spectrum of autoimmune disease.


Axolabs is a custom research organization providing high-end preclinical solutions and consultancy in the field of oligonucleotide therapeutics and nucleic acid medicines.

Axolabs is developing a bioanalytical method for analyzing Aptahem’s lead candidate Apta-1.


Accelera supports all stages of the Drug Discovery and Development process to translate new chemical entities into novel medicines.

Accelera is performing the non-clinical toxicology program on Aptahem’s lead candidate Apta-1.


PKxpert AB provides consultancy services & scientific expert knowledge to pharmaceutical companies in areas: pharmacokinetics, toxicokinetics (according to GLP), drug metabolism and ADME, regulatory documentation, project management and quality assurance (QA) activities according to GxP, including audits and SOP documentation.


Hooke Laboratories is a full-service pre-clinical contract research organization (CRO) specializing in rodent models of inflammation and autoimmune diseases.

Hooke Laboratories work together with Aptahem in in vivo animal models.

Seattle Children’s Research Institute

Seattle Children’s Research Institute is ranked fifth in the nation among pediatric research centers for National Institutes of Health funding. Investigators are involved in projects covering every phase of research, from studying how diseases work to improving investigational therapies. Seattle Children’s researchers work in close collaboration with each other, and with colleagues at partner institutions and healthcare providers. These collaborations allow the faculty to draw on a variety of disciplines and techniques as they pursue solutions to some of medicine’s most complex problems.

Seattle Children’s Research Institute will together with Aptahem study the effect of Apta-1 treatment on infectious sepsis animal models and also in in vitro studies.


Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 7,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 7.2 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit

Recipharm will develop the pharmaceutical formulation of Apta-1 for the first clinical trial.